January 2009 in “Side effects of drugs annual” Some blood-thinning medications can increase the risk of bleeding, and certain factors like genetics and other health conditions affect their safety and effectiveness.
130 citations
,
October 2006 in “Allergy” Allergic reactions to blood thinners are rare but can be serious, requiring careful testing and alternative treatments.
28 citations
,
September 2008 in “Current Pharmaceutical Design” Allergic reactions to blood thinners are rare but can be serious, requiring careful management and alternative treatments.
8 citations
,
September 2004 in “Contact dermatitis” Avoiding dyed wigs and clothing improved severe allergic reactions in a woman treated with diphencyprone.
June 2025 in “British Journal of Dermatology” Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
January 2026 in “Clinical and Experimental Dermatology” Ruxolitinib helped a patient with alopecia areata regrow hair.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.
37 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Ruxolitinib can help regrow hair in severe alopecia areata.
1 citations
,
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
October 2025 in “Pharmaceuticals” Auranofin shows promise as a cancer treatment, especially when combined with other therapies.
51 citations
,
July 2003 in “Annals of the Rheumatic Diseases” Co-trimoxazole may help treat autoimmune diseases.
September 2025 in “Bioengineering” The framework helps predict adverse effects of blood thinners, improving drug selection for atrial fibrillation.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
71 citations
,
May 2024 in “New England Journal of Medicine” Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.
36 citations
,
July 2017 in “Journal of controlled release” A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.
November 2016 in “Therapeutic Delivery” New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.
September 2023 in “Journal of the American Academy of Dermatology” Ixekizumab is safe for long-term use with low rates of major heart-related events.
4 citations
,
April 2024 in “Journal of Drugs in Dermatology” Ruxolitinib cream may help treat severe hair loss in children.
May 2026 in “Journal of Human Immunity” Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.
2 citations
,
November 2004 in “Blood” RXRa is crucial for Th2 immune cell development and may link nutrition to immune health.
2 citations
,
December 2023 in “Stem Cells Translational Medicine” ISX-9 helps stem cells heal lung injury better by boosting growth factor secretion.
January 2021 in “대한본초학회지(본초분과학회지)” Achyranthis Radix ethanol extract helps hair grow.
August 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
2 citations
,
November 2024 in “AAPS PharmSciTech” Spanlastic formulations improve rivaroxaban's oral anticoagulation efficiency.
March 2026 in “Preprints.org” Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.
October 2025 in “Frontiers in Medicine” Ixekizumab has known and some unexpected side effects.
ISX9 helps regrow hair by activating a specific cell signaling pathway.
October 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” The new aptamer TAGX-0003 shows promise as an effective treatment for hair loss disorder alopecia areata.